IMPEDIMED LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.08 AUD | 0.00% |
|
-11.11% | -44.83% |
| 04-30 | ImpediMed's Qaurterly Revenue Rises in Fiscal Q3; Shares Fall 8% | MT |
| 04-30 | Transcript : ImpediMed Limited, Q3 2024 Earnings Call, Apr 30, 2024 |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -44.83% | 105M | C | ||
| +8.33% | 219B | B | ||
| +6.72% | 183B | B- | ||
| +10.18% | 132B | B- | ||
| +24.91% | 106B | A- | ||
| -2.47% | 62.09B | A- | ||
| +10.56% | 50.8B | B+ | ||
| +4.81% | 50.88B | B+ | ||
| -0.24% | 40.64B | A | ||
| +1.22% | 35.71B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- IPD Stock
- Ratings ImpediMed Limited
